| abstract |
A method for a prophylaxis, suppression or elimination of an allergic reaction in a human, or for shifting the TH1-TH2 balance in a human body toward an increase of TH1 or a decrease of TH2 or both an increase in TH1 and a decrease in TH2, includes the steps of preparing a pharmaceutical composition having genomic DNA of at least one probiotic, gram-positive bacteria strain selected from the group Lactobacillus gasseri PA 16/8, Bifidobacterium bifidum MF 20/5, Bifidobacterium bifidum MG 20/5, Bifidumbacterium longum SP 07/3, Lactobacillus rhamnosus GG (92164) or a combination thereof, as an active ingredient, the at least one probiotic, gram-positive bacteria strain being present in the form of at least one of viable bacteria and inactivated bacteria, and administering to a human as suppository, vaginally, as a cream applied to skin, rectally, as a subcutaneous injection, as intravenous injection, as an inhalation liquid, or orally in combination with food. |